[go: up one dir, main page]

de Carvalho et al., 2012 - Google Patents

Cancer/Testis Antigen MAGE‐C1/CT7: New Target for Multiple Myeloma Therapy

de Carvalho et al., 2012

View PDF @Full View
Document ID
7083832839612892196
Author
de Carvalho F
Vettore A
Colleoni G
Publication year
Publication venue
Journal of Immunology Research

External Links

Snippet

Cancer/Testis Antigens (CTAs) are a promising class of tumor antigens that have a limited expression in somatic tissues (testis, ovary, fetal, and placental cells). Aberrant expression of CTAs in cancer cells may lead to abnormal chromosome segregation and aneuploidy. CTAs …
Continue reading at onlinelibrary.wiley.com (PDF) (other versions)

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES OR MICRO-ORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or micro-organisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Hybridisation probes
    • C12Q1/6883—Hybridisation probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Hybridisation probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens

Similar Documents

Publication Publication Date Title
de Carvalho et al. Cancer/Testis Antigen MAGE‐C1/CT7: New Target for Multiple Myeloma Therapy
US11016091B2 (en) Identification, selection and use of high curative potential T cell epitopes
Leko et al. Identifying and targeting human tumor antigens for T cell-based immunotherapy of solid tumors
Scanlan et al. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy
Codd et al. Cancer stem cells as targets for immunotherapy
Greiner et al. Mutated regions of nucleophosmin 1 elicit both CD4+ and CD8+ T-cell responses in patients with acute myeloid leukemia
Gjerstorff et al. Oncogenic cancer/testis antigens: prime candidates for immunotherapy
Wirth et al. Neoantigen targeting—dawn of a new era in cancer immunotherapy?
Salmaninejad et al. Cancer/testis antigens: expression, regulation, tumor invasion, and use in immunotherapy of cancers
Leisegang et al. Eradication of large solid tumors by gene therapy with a T-cell receptor targeting a single cancer-specific point mutation
Bobisse et al. Neoantigen-based cancer immunotherapy
Brennick et al. Neoepitopes as cancer immunotherapy targets: key challenges and opportunities
AU2014264943B2 (en) Predicting immunogenicity of T cell epitopes
Mennonna et al. T cell neoepitope discovery in colorectal cancer by high throughput profiling of somatic mutations in expressed genes
Nin et al. Biology of cancer-testis antigens and their therapeutic implications in cancer
Fasso et al. SPAS-1 (stimulator of prostatic adenocarcinoma-specific T cells)/SH3GLB2: A prostate tumor antigen identified by CTLA-4 blockade
Gjerstorff et al. An overview of the GAGE cancer/testis antigen family with the inclusion of newly identified members
Kiyotani et al. Immunopharmacogenomics towards personalized cancer immunotherapy targeting neoantigens
Nielsen et al. Toward personalized lymphoma immunotherapy: identification of common driver mutations recognized by patient CD8+ T cells
Kalina et al. Mutational analysis of gene fusions predicts novel MHC class I–restricted T-cell epitopes and immune signatures in a subset of prostate cancer
Koşaloğlu et al. Identification of immunotherapeutic targets by genomic profiling of rectal NET metastases
Zhang et al. Research progress of neoantigen-based dendritic cell vaccines in pancreatic cancer
Apavaloaei et al. Induced pluripotent stem cells display a distinct set of MHC I-associated peptides shared by human cancers
Want et al. Nature of tumour rejection antigens in ovarian cancer
Rosa et al. Germ cell proteins in melanoma: prognosis, diagnosis, treatment, and theories on expression